{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:52:41Z","timestamp":1792356761190,"version":"4.4.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/bor.0000000000000031","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T17:20:03Z","timestamp":1388424003000},"page":"162-168","source":"Crossref","is-referenced-by-count":35,"title":["Safety profile of anti-gout agents"],"prefix":"10.1097","volume":"26","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis.","volume":"4","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","article-title":"Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.","volume":"96","author":"Cronstein","year":"1995","journal-title":"J Clin Invest"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare.","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy.","volume":"316","author":"Kuncl","year":"1987","journal-title":"N Engl J Med"},{"key":"R6-11-20210128","first-page":"67","article-title":"Colchicine neuromyopathy in a renal transplant patient with normal muscle enzyme levels.","volume":"42","author":"Cook","year":"1994","journal-title":"Clin Nephrol"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/00007890-199006000-00041","article-title":"Colchicine neuromyopathy after renal transplantation.","volume":"49","author":"Rieger","year":"1990","journal-title":"Transplantation"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/03009749609069217","article-title":"Colchicine myopathy.","volume":"25","author":"Tapal","year":"1996","journal-title":"Scand J Rheumatol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0303-8467(97)00092-9","article-title":"Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients.","volume":"99","author":"Rana","year":"1997","journal-title":"Clin Neurol Neurosurg"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S1053-2498(00)00175-3","article-title":"Postcardiac transplantation gout: incidence and therapeutic complications.","volume":"19","author":"Wluka","year":"2000","journal-title":"J Heart Lung Transplant"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.20102","article-title":"Quality of care indicators for gout management.","volume":"50","author":"Mikuls","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout.","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheumatol"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease.","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P4503A4P-glycoprotein inhibitors.","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1 and the inflammasome in gout: implications for therapy.","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double blind trials and their initial extensions.","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rhem Dis"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for acute gout flare during initiation of uric acid lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatology"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/0091270012439715","article-title":"Clinical Risk Factors for adverse events in allopurinol users.","volume":"53","author":"Ryu","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Sem Dial"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency.","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"R24-11-20210128","first-page":"1361","article-title":"Severe allopurinol hypersensitivity syndrome.","volume":"72","author":"Lupton","year":"1979","journal-title":"J Am Acad Dermatol"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality.","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007611-197911000-00004","article-title":"Severe hypersensitivity reactions to allopurinol.","volume":"72","author":"Lang","year":"1979","journal-title":"South Med J"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.1974.00320210163026","article-title":"Severe allopurinol hypersensitivity.","volume":"134","author":"Young","year":"1974","journal-title":"Arch Int Med"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review.","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","article-title":"Strong association between HLA-B5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.","volume":"19","author":"Tassaneeyakul","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high risk drugs.","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.rhu.0000164822.98163.22","article-title":"Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight into allopurinol related toxicity.","volume":"11","author":"Perez-Ruiz","year":"2005","journal-title":"J Clin Rheumatol"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1136\/ard.60.10.981","article-title":"Relationship between adverse events associated with allopurinol and renal function in patients with gout.","volume":"60","author":"Vazquez-Mellado","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R35-11-20210128","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout.","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2217\/pgs.12.89","article-title":"HLA-B58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese.","volume":"13","author":"Cao","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2133.2012.10894.x","article-title":"Association between HLA-B58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong.","volume":"167","author":"Chiu","year":"2012","journal-title":"Br J Dermatol"},{"key":"R38-11-20210128","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/clpt.2012.209","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.","volume":"93","author":"Hershfield","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"R39-11-20210128","first-page":"S107","article-title":"A prospective study of HLA-B5801 genotyping for the prevention of allopurinol induced severe cutaneous adverse reactions.","volume":"91","author":"Lee","year":"2012","journal-title":"Clin Pharm Ther"},{"key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/1756-185X.12050","article-title":"HLA-B5801: utility and cost effectiveness in the Asia-Pacific region.","volume":"16","author":"Yeo","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"R41-11-20210128","first-page":"411","article-title":"Initiating allopurinol therapy: do we need to know the patients human leucocyte antigen status Int Med","volume":"42","author":"Lee","year":"2012","journal-title":"J"},{"key":"R42-11-20210128","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2133\/dmpk.DMPK-11-NT-120","article-title":"Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrometoxic epidermal necrolysis in Japanese.","volume":"27","author":"Maekawa","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"R43-11-20210128","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in chronic gout, including in those with renal impairment.","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R44-11-20210128","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600mgday versus benzbromarone 100-200mgday in patients with gout.","volume":"68","author":"Reinders","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R45-11-20210128","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/RHU.0b013e31829372e6","article-title":"Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol.","volume":"19","author":"Paisanainsup","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for the Management of Gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R47-11-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2318-12-11","article-title":"The efficacy and safety of febuxostat for urate lowering in gout patients 65 years of age.","volume":"12","author":"Jackson","year":"2012","journal-title":"BMC Geriatr"},{"key":"R48-11-20210128","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/dom.12135","article-title":"Diabetes and gout: efficacy and safety of febuxostat and allopurinol.","volume":"15","author":"Becker","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R49-11-20210128","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.semarthrit.2012.11.002","article-title":"Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.","volume":"42","author":"Gandhi","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"R50-11-20210128","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ahj.2012.04.011","article-title":"Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.","volume":"164","author":"White","year":"2012","journal-title":"Am Heart J"},{"key":"R51-11-20210128","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3899\/jrheum.110092","article-title":"Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.","volume":"38","author":"Chohan","year":"2011","journal-title":"J Rheumatol"},{"key":"R52-11-20210128","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3899\/jrheum.111161","article-title":"Febuxostat hypersensitivity.","volume":"39","author":"Abeles","year":"2012","journal-title":"J Rheumatol"},{"key":"R53-11-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10157-012-0763-7","article-title":"Febuxostat for hyperuricaemia: experience with patients on chronic hemodialysis treatment.","volume":"17","author":"Horikoshi","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"R54-11-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.","volume":"306","author":"Sundy","year":"2011","journal-title":"J Am Med Assoc"},{"key":"R55-11-20210128","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/annrheumdis-2012-201795","article-title":"Long-term safety of pegloticase in chronic gout refractory to conventional treatment.","volume":"72","author":"Becker","year":"2013","journal-title":"Ann Rhem Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:31:39Z","timestamp":1620948699000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201403000-00011"}},"subtitle":["an update"],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000031","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}